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Summary Statins decrease serum levels of low-density lipoprotein (LDL) cholesterol and
have pleiotropic effects. Statin therapy may have beneﬁcial effects on the clinical outcome in
patients with heart failure (HF). HF is associated with lipoprotein components. A recent study
suggested that lower levels of high-density lipoprotein (HDL) cholesterol were the strongest
predictor of worsening HF. In addition, serum total cholesterol (TC) is a prognostic factor for
patients with HF. Although the levels of HDL cholesterol, apolipoprotein (Apo) A-I, triglyceride,
TC, and LDL cholesterol may be associated with the onset of HF and/or an adverse prognosis
in patients with HF, it is not yet clear which lipoprotein plays the most important role in this
context. Among these lipoproteins, HDL protects against cardiovascular events by mediating
the enhancement of reverse cholesterol transport. Moreover, HDL also has pleiotropic effects,
such as anti-oxidant, anti-inﬂammatory, and anti-thrombotic properties. An increase in HDL
cholesterol or ApoA-I, the principal Apo of HDL, may be a therapeutic target in HF. Therefore,
we discuss here the usefulness of statins and lipoprotein metabolism for preventing HF.
© 2010 Japanese College of Cardiology. Published by Elsevier Ireland Ltd. All rights reserved.
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ntroductiontatins, which are potent inhibitors of 3-hydroxy-3-
ethyl-glutaryl-coenzyme A reductase (HMG-CoA), inhibit
holesterol biosynthesis and decrease serum levels of
Published by Elsevier Ireland Ltd. All rights reserved.
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Table 1 Pleiotropic effects of statins.
Effects Ref. no.
Blocking cardiac hypertrophy [7]
Vasodilatation and improvement of
endothelial function
[8]
Preventing myocardial ischemia and
vascular remodeling
[8]
Decreasing plasma levels of tumor
necrosis factor, interleukin-6, and
C-reactive protein
[9]
Inhibition of matrix
metalloproteinase activation
[10]
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levels and reduce renal
sympathetic nerve activity
[11]
ow-density lipoprotein (LDL) cholesterol. In addition to
heir main effects, statins also have pleiotropic effects, such
s anti-inﬂammatory and anti-oxidant effects, and improve
ndothelial function and angiogenesis [1,2]. Statins have pri-
ary and secondary effects that help to prevent against
he development of coronary artery disease (CAD) [3]. Heart
ailure (HF) is one of the most common diseases in the indus-
rial world because any heart disease can ultimately lead to
F. Although HF is induced by CAD and the treatment of CAD
atients with statins results in a signiﬁcant decrease in mor-
ality [4—6], the potential beneﬁts of statins in HF remain
nclear. In addition, serum total cholesterol (TC) is a novel
rognostic factor for patients with HF. Although the levels
f high-density lipoprotein (HDL) cholesterol, apolipopro-
ein (Apo) A-I, triglyceride (TG), TC, and LDL cholesterol
re associated with the onset of HF and/or an adverse prog-
osis in patients with HF, it is not yet clear which lipoprotein
lays the most important role in this context.
HDL protects against cardiovascular events through the
nhancement of reverse cholesterol transport. Moreover,
DL also has pleiotropic effects, such as anti-oxidant, anti-
nﬂammatory, and anti-thrombotic properties. An increase
n HDL cholesterol or ApoA-I, the principal Apo of HDL, may
e a therapeutic target in HF. This review addresses the clin-
cal beneﬁts of statins in patients with HF and the role of
ipoprotein metabolism in the prevention of HF.
tatin therapy in HF
tatins have pleiotropic effects (Table 1). They have been
hown to block the development of cardiac hypertrophy
hrough the inhibition of Rho and Ras pathways [7]. In
ddition, they induce vasodilatation and improve endothe-
ial function through an increase in nitric oxide production
8] and rescue myocardial ischemia and vascular remod-
ling. Although HF is associated with the activation of
ro-inﬂammatory cytokines, statins decrease plasma lev-
ls of tumor necrosis factor-, interleukin-6, and C-reactive
rotein in patients with nonischemic HF [9]. Statins inhibit
he activation of matrix metalloproteinase, ﬁbrosis, and
yocardial apoptosis in experimental myocardial infarction
10]. Statins also decrease plasma norepinephrine levels and
educe renal sympathetic nerve activity after experimental
A
C
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F [11]. Based on this basic research, statin therapy should
mprove the mortality in HF independent of its lipid-lowering
ffect.
Statin therapy is beneﬁcial in reducing major cardiovas-
ular events associated with CAD [12,13]. Although statins
ave not been administered routinely to HF patients, clini-
al trials have shown that statin therapy is effective in the
rognosis of HF. In the Kaiser Permanente Chronic Heart
ailure cohort, statin therapy was associated with a lower
elative risk of death and hospitalization for HF [4]. Statin
herapy was associated with improvements in mortality in
lder patients with HF [5]. In addition, simvastatin reduces
he occurrence of HF in patients with CAD without previ-
us evidence of HF regardless of the TC level or CAD status
n long-term prevention [6]. After these cohort and retro-
pective trials, randomized clinical trials were required to
etermine the role of statins in improving outcomes in the
arge and growing population of patients with HF.
Recently, important randomized large-scale clinical trials
ave been reported [14—16]. In the controlled rosuvastatin
ultinational study in heart failure (CORONA), rosuvastatin
id not reduce the primary outcome or the number of deaths
rom any cause in older patients with systolic HF (New York
eart Association (NYHA) Class II—IV, ischemic, systolic HF),
lthough it did reduce the number of HF hospitalizations
14]. The Gruppo Italiano per lo Studio della Sopravvivenza
ell’Insufﬁcienza Cardiaca Heart Failure (GISSI-HF) trial also
ndicated that rosuvastatin did not affect clinical outcomes
n patients with chronic HF with any cause [15]. In addi-
ion, rosuvastatin lowered LDL cholesterol levels, but had no
igniﬁcant effect on death from cardiovascular causes, non-
atal myocardial infarction, or nonfatal stroke in patients
ith end-stage renal disease [A Study to Evaluate the Use
f Rosuvastatin in Subjects on Regular Hemodialysis: An
ssessment of Survival and Cardiovascular Events (AURORA)]
16]. These trials used rosuvastatin, in contrast to previ-
us trials that used more lipophilic statins, and the CORONA
tudy enrolled older patients with more advanced HF. Pos-
ible explanations for the negative ﬁndings may include the
hoice of statins, differences in dosage, and the patient
ackground.
On the other hand, the results of a small-scale trial sug-
ested that atorvastatin may beneﬁt patients with HF and
iabetes mellitus by improving ventricular electrical stabil-
ty and decelerating the deterioration of renal function [17].
n addition, a meta-analysis was performed using 13 stud-
es, of which 11 were retrospective analyses and 2 were
rospective trials (Fig. 1) [1]. Statin use in HF patients was
ssociated with a signiﬁcant 26% decrease in the relative
isk of mortality [hazard ratio (HR) = 0.74; 95% conﬁdence
nterval (CI) = 0.68—0.8]. HRs for HF of ischemic and non-
schemic etiology were 0.73 (95% CI = 0.65—0.82) and 0.73
95% CI = 0.61—0.87), respectively (8 of the 13 studies).
lthough a meta-analysis has several limitations, the results
how a signiﬁcant reduction in mortality with statin use in
atients with HF.ssociation between lipid proﬁle and HF
ardiac and renal dysfunctions frequently coexist. This is
eferred to as the cardio-renal syndrome. In patients with
Effects of statin and lipoprotein metabolism in heart failure
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hFigure 1 Mortality among patients with heart failure (total
13 studies, 8 ischemic and 8 nonischemic studies).
renal failure (RF), the lipid proﬁle shows higher serum
TG, very low-density lipoprotein (VLDL) and intermittent-
density lipoprotein (IDL) levels, and lower LDL cholesterol
and HDL cholesterol levels according to the disturbance of
the catabolism of VLDL and IDL. The lipid proﬁle in HF is
similar to that in RF. There have been several reports on
the association between serum cholesterol levels and HF in
humans (Table 2). Horwich et al. reported that serum TC is a
novel prognostic factor for patients with advanced HF [18].
Lower TC levels independently predict increased in-hospital
mortality risk [19]. Although a reduced left ventricular
(LV) ejection fraction, a high NYHA class, and increased LV
end-diastolic diameter were strong risk factors associated
with the endpoint [20], decreased TC and HDL cholesterol
levels were also identiﬁed as weak predictors of risk. In
addition, data regarding lipid proﬁles, including serum TC,
TG, HDL cholesterol, and LDL cholesterol were obtained
after the improvement of HF and discharge from the hos-
pital [21], and 21 patients died during the follow-up period
(2.3± 0.9 years). In this report, there was a signiﬁcant dif-
ference between survivors and nonsurvivors with regard to
HDL cholesterol (53± 15 and 43± 15mg/dl, respectively,
p < 0.01), but no differences were observed in other vari-
ables. These trials indicated that lower serum LDL and/or
Table 2 Lipid proﬁle and prognosis in HF patients.
Lipid proﬁle Prognosis Ref. no.
TC level Prognostic factor [18]
Lower TC Increasing
in-hospital
mortality risk
[19]
Decreased TC and
HDL cholesterol
Risk predictors [20]
HDL cholesterol Survivors > nonsurvivors [21]
HDL, high-density lipoprotein; HF, heart failure; TC, total choles-
terol.
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DL cholesterol levels are associated with a worse progno-
is in patients with HF, since HF patients may require more
nergy for protecting against inﬂammation and activating
he immune system. In fact, higher baseline levels of LDL
holesterol, HDL cholesterol, ApoA-I, ApoB, and TG were
ssociated with a better prognosis in HF patients [22].
Since HDL has pleiotropic effects, such as anti-oxidant,
nti-inﬂammatory, and anti-thrombotic properties, and
ince lower serum HDL cholesterol levels are associated with
worse prognosis in patients with HF, an increase in HDL or
mprovement in HDL function should decrease the mortality
n HF patients depending on and/or independent of its main
unction of enhancing reverse cholesterol transport.
poA-I as a therapeutic target for the
revention of HF
poA-I is one of the most important components of
polipoprotein in HDL. Lipoprotein components have usually
ot been recognized as risk factors for the development of
F. However, low levels of ApoA-I are independently associ-
ted with an adverse prognosis in patients with nonischemic
F [23]. Ingelsson et al. reported that the ApoB/ApoA-I-
atio (HR = 1.27, 95% CI = 1.09—1.48) was associated with an
ncreased risk of the development of HF [24]. Lorgelly et
l. studied the biomarkers in prognostic models in HF, and
ound that ApoA-I more strongly predicted a range of clin-
cal outcomes than LDL cholesterol or HDL cholesterol (or
he LDL/HDL ratio) [22]. In addition, HF is associated with
ipoprotein components in statin-treated patients with CAD.
ariables related to LDL cholesterol less strongly predicted
ew-onset congestive HF than those related to HDL choles-
erol, and ApoA-I was the single variable that was most
trongly associated with HF [25]. Why would ApoA-I be the
ost strongly predictive lipidemic factor?
In an experimental study, ApoA-I gene transfer reduced
he development of streptozotocin-induced diabetic car-
iomyopathy. This ApoA-I gene transfer-mediated pro-
ection was associated with a 1.6-, 1.6-, and 2.4-fold
nduction of diabetes-downregulated phospho to Akt,
ndothelial nitric oxide synthase, and the glycogen syn-
hase kinase ratio, respectively, and gene transfer reduced
yperglycemia-induced cardiomyocyte apoptosis by 3.4-fold
26]. Moreover, we have been studying the use of recon-
tituted (r) HDL therapy for preventing the progression of
oronary atherosclerosis [27—29]. rHDL (containing ApoA-I)-
romoted cell survival has beneﬁcial morphological effects
hat help to prevent LV remodeling and improve function
fter myocardial infarction, and may prevent the arrest of
ell growth through an extracellular-regulated kinase path-
ay in myocytes [28]. Therefore, ApoA-I may be a target
ipidemic factor for preventing HF.
onclusions
tatin therapy has primary and secondary effects that help
rotect against the development of CAD. Although HF is
ainly induced by CAD and CAD patients treated with statins
how a signiﬁcant decrease in mortality, we cannot conﬁrm
hat cholesterol levels need to be lower in patients with HF
t this stage. Actually, a cohort study indicated that about
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[90
0% of HF patients received statins at discharge, and a lower
ercentage was seen in Japan [30]. Therefore, we should not
se statins in every patient with HF until more useful data
re available.
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